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Dengue virus (DV) is a positive-strand RNA virus of the Flavivirus genus. It is one of the
most prevalent mosquito-borne viruses, infecting globally 390 million individuals per year.
The clinical spectrum of DV infection ranges from an asymptomatic course to severe
complications such as dengue hemorrhagic fever (DHF) and dengue shock syndrome
(DSS), the latter because of severe plasma leakage. Given that the outcome of infection
is likely determined by the kinetics of viral replication and the antiviral host cell immune
response (HIR) it is of importance to understand the interaction between these two
parameters. In this study, we use mathematical modeling to characterize and understand
the complex interplay between intracellular DV replication and the host cells’ defense
mechanisms. We first measured viral RNA, viral protein, and virus particle production
in Huh7 cells, which exhibit a notoriously weak intrinsic antiviral response. Based on
these measurements, we developed a detailed intracellular DV replication model. We
then measured replication in IFN competent A549 cells and used this data to couple
the replication model with a model describing IFN activation and production of IFN
stimulated genes (ISGs), as well as their interplay with DV replication. By comparing the
cell line specific DV replication, we found that host factors involved in replication complex
formation and virus particle production are crucial for replication efficiency. Regarding
possible modes of action of the HIR, our model fits suggest that the HIR mainly affects
DV RNA translation initiation, cytosolic DV RNA degradation, and naïve cell infection. We
further analyzed the potential of direct acting antiviral drugs targeting different processes
of the DV lifecycle in silico and found that targeting RNA synthesis and virus assembly
and release are the most promising anti-DV drug targets.
Keywords: dengue virus, mathematical model, innate immune response, virus replication, computational
simulation
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INTRODUCTION
Dengue virus (DV) is the most prevalent vector-borne virus
in the world, with an estimated global number of 390 million
new infections annually, thereof 90 million with clinical
manifestations, including severe dengue disease (Bhatt et al.,
2013). DV poses a huge burden on human populations and
health systems in affected countries, and significantly impacts
the economy in tropical countries, including the southern
United States (WHO, 2012). Fueled by climate change and
globalization and accelerated further by viral evolution, the
expansion of DV is expected to increase further (Murray et al.,
2013). DV is transmitted mainly by female Aedesmosquitos, and
with the spread of its vector, DV is spreading as well (Campbell
et al., 2015). In consequence, the global incidence of DV infection
has already risen 30-fold during the past 50 years. Infection
with DV causes flu-like symptoms but is occasionally associated
with severe complications. The fatality rate of dengue infection
is between 1 and 5%, and below 1% with proper symptomatic
treatment (Ranjit and Kissoon, 2011). There is no antiviral
therapy available against DV, and the recently approved vaccine
has limited efficacy and depends on baseline serostatus of the
vaccine recipient (World Health Organization, 2016).
DV infects dendritic cells (DC), B cells, T cells, monocytes,
macrophages, but also the liver. DV is an enveloped, positive-
sense (+)RNA virus of the Flaviviridae family within the genus
Flavivirus, consisting of four distinct serotypes (DV1/2/3/4).
Its approximately 10.7 kb genome encodes the three structural
proteins capsid (C), precursor membrane (prM), and envelope
(E) protein and seven non-structural proteins (NS1, NS2A, NS2B,
NS3, NS4A, NS4B, and NS5). Upon entry into the host cell,
the viral RNA genome is translated at the rough endoplasmic
reticulum (rER) giving rise to a polyprotein, ∼3,400 amino acids
in length, which is co- and post-translationally cleaved by viral
and host proteases into the structural and non-structural proteins
(Neufeldt et al., 2018). DV induces membrane alterations at the
rER, forming membrane invaginations. The viral RNA genome
is amplified in these replication compartments (RC), starting
with minus-strand synthesis to obtain a double-stranded RNA
(dsRNA) intermediate which then serves as template for further
plus-strand synthesis. The newly synthesized viral (+)RNA
genomes leave the RC and are then either packaged into virions,
which after maturation are released from the infected cell, or
are again used for the next round of viral RNA translation
(Bartenschlager and Miller, 2008; Rodenhuis-Zybert et al., 2010;
Tuiskunen Bäck and Lundkvist, 2013; Screaton et al., 2015).
Abbreviations: AIC, Aikaike’s information criterion; (+)RNA, Positive-sense
RNA; DAA, Direct acting antiviral; DC, Dendritic cell; DF, Dengue fever;
DHF, Dengue haemorrhagic fever; dsRNA, Double-stranded RNA; DSS, Dengue
shock syndrome; DV, Dengue virus; rER, Rough Endoplasmic reticulum; HIR,
Host cell immune response; HCV, Hepatitis C virus; HF, Host factor; hpi,
hours post infection; IFN, Interferon; IIR, Innate immune response; ISG,
Interferon stimulated gene; JAK, Janus kinase; MDA-5, Melanoma differentiation
associated gene-5; MOI, Multiplicity of infection; NS, Non-structural protein;
ODE, Ordinary differential equations; PRR, Pattern recognition receptor; RC,
Replication compartment; RIG-I, Retinoic acid inducible gene-I; RLR, RIG-I like
receptors; STAT, Signal transducer and activator of transcription factor; TLR,
Toll-like receptors; WHO, World health organization.
The host cell’s defense against DV is mediated via pattern
recognition receptors (PRRs), in case of DV mainly via the
endosomal Toll-like receptors (TLR3/TLR7/TLR8) and the
cytosolic RNA helicases retinoic acid inducible gene I (RIG-
I) and melanoma differentiation associated gene 5 (MDA-5)
(Muñoz-Jordán and Fredericksen, 2010; Morrison et al., 2012).
TLR3 recognizes dsRNA, while TLR7 and TLR8 recognize viral
single-stranded RNA (Xagorari and Chlichlia, 2008). All three
TLRs activate signaling cascades that lead to the production
of interferon α/β (IFN α/β) and inflammatory cytokines. RIG-
I/MDA-5 signals via mitochondrial antiviral signaling protein
(MAVS) and tumor necrosis factor receptor-associated factor
3 (TRAF3), activating tank-binding kinase 1 (TBK1) and
ultimately phosphorylating interferon regulatory factor 3 (IRF3)
and activating nuclear factor kappa B (NF-κB). The subsequent
type I (α/β) and type III (λ) IFN production induces the
activation of hundreds of IFN stimulated genes (ISGs), bringing
the cells into an antiviral state and resulting in an inhibition
of DV (Nasirudeen et al., 2011; Tuiskunen Bäck and Lundkvist,
2013; Dalrymple et al., 2015).
DV, however, is not defenseless, and has evolved a number of
mechanisms antagonizing the antiviral response of the cell both
at the level of activation of the host cell immune response (HIR)
and the induced effector phase. For instance, 2’-O-methylation of
the DV RNA genome, mediated by NS5, was shown to slow down
the activation kinetics of the IFN response (Schmid et al., 2015).
In addition, the DV NS2B-3 protease cleaves the stimulator of
interferon genes (STING), thus reducing type I IFN production
(Diamond and Pierson, 2015). In fact, several groups have shown
that the suppression of the early IFN induction by DV is critical
for successful virus infection and replication (Shresta et al.,
2004; Perry et al., 2009). Moreover, Schmid et al. (2015) have
shown that the ability of IFN to control DV spread might be
stochastic and “leaky.” While secreted IFN protects surrounding
naïve cells from infection, this protection is incomplete with
cells infected with DV prior to activation of the IFN response
(Schmid et al., 2015). DV replication occurs inside membrane
vesicles corresponding to invaginations into the rER lumen, likely
shielding viral dsRNA intermediates from recognition by the
HIR (Welsch et al., 2009). At the level of the effector phase,
DV NS5, which contains the enzymatic activity for capping and
amplification of the viral RNA genome, was shown to bind to
and induce the degradation of the signal transducer and activator
of transcription factor (STAT) 2 via a proteasome-dependent
mechanism (reviewed in Neufeldt et al., 2018), thus blocking
ISG induction downstream of the IFN receptor. Therefore, the
interplay between DV and the innate immune response (IIR) is
complex, and its exact magnitude and dynamics likely impact and
possibly determine clinical outcome of the infection.
Mathematical modeling is a valuable tool to study complex
dynamical systems and has been employed to analyze infection
dynamics for a number of different viruses (Zitzmann and
Kaderali, 2018). Most previous work on modeling viral infection
has built on the basic model introduced by Nowak and
Bangham (1996) and Nowak et al. (1996), focusing on the
dynamics of susceptible cells, infected cells, and virus at the
cell population level. Especially, the within-host dynamics of
human immunodeficiency virus (HIV) and hepatitis C virus
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(HCV) have been studied in detail with simple models on the cell
population scale with regard to the antiviral immune response
and treatment opportunities (Ho et al., 1995; Wei et al., 1995;
Perelson et al., 1996, 1997; Bonhoeffer et al., 1997; Neumann,
1998; Stafford et al., 2000; Perelson, 2002; Rong and Perelson,
2009; Perelson and Ribeiro, 2013; Perelson and Guedj, 2015).
In the case of DV modeling, these so-called target cell-limited
models have been linked to the adaptive immune response via
modeling of antibodies and T cell responses (Clapham et al.,
2014; Ben-Shachar et al., 2016), and the IIR by IFN (Ben-
Shachar and Koelle, 2014; Schmid et al., 2015). Several authors
have furthermore developed intracellular replication models for
related viruses (Dahari et al., 2007; Heldt et al., 2012, 2013; Binder
et al., 2013; Guedj et al., 2013; Clausznitzer et al., 2015; Laske
et al., 2016; Benzine et al., 2017; Aunins et al., 2018), but to
our knowledge there is no mathematical model describing the
intracellular steps of DV replication to date. In this manuscript,
we focus on the highly dynamic initial phase post cell infection
and developed a detailed differential equations model capable
of quantitatively describing the intracellular infection dynamics.
We measured viral replication in two different cell lines, Huh7
cells (with very little HIR) and A549 cells (with high HIR
competence). By integrating the main steps of the HIR into the
model, we were able to describe the infection kinetics in both cell
types. Our investigation focuses on the cell line-specific impact
of host factors, which determine RNA synthesis efficiency, and
the involvement of the HIR. Using our mathematical model,
we identified possible antiviral modes of action of the HIR on
the DV lifecycle and the viral countermeasures suppressing DV
recognition and activation of the HIR. We further identified
the most sensitive processes in the DV lifecycle, which might
constitute promising antiviral drug targets, and we evaluated
possible antiviral intervention strategies in silico.
MATERIALS AND METHODS
Measuring DV Replication in Huh7 and
A549 Cells
Cell Lines
A549 and Huh7 cells were cultivated at 37◦C, 5% CO2 in of
DMEMcplt (2 mmol/L L-glutamine, non-essential amino acids,
100 U/ml penicillin, 100µg/ml streptomycin and 10% fetal
calf serum).
Kinetics Experiments (120830 and 120921)
2 × 105 A549 and Huh7 cells were seeded 1 day prior infection.
Cells were infected with DV reporter virus expressing Renilla
Luciferase (Schmid et al., 2015) at a MOI of 10. After 1 h, the
inoculum was removed and cells washed thrice with sterile PBS
prior addition of DMEMcplt. Cells were incubated at 37◦C for
the indicated time points.
Infectivity Titers
Supernatants were harvested and filtered through a 0.45 µm-
pore size membrane. Supernatants were supplemented with
15mM HEPES and stored at −80◦C. Infectivity titers of virus
supernatants were determined by limiting dilution assay using
Huh7.5 cells as described elsewhere (Lindenbach et al., 2005).
Interferon Lambda ELISA
Supernatants of infected cells were supplemented with 1%
(v/v) Triton X-100 to inactivate DENV infectious particles
and subsequently stored at −80◦C until further use. Interferon
lambda protein release was determined by VeriKine-DIYTM
Human Interferon Lambda/IL-28B/29/28A ELISA (PBL
Interferon Source, USA) with an assay range of 62.5 to 4,000
pg/ml. ELISA procedure was conducted according to the
manufacturer’s protocol using high binding 96 well ELISA
microplates (Greiner Bio-One, Frickenhausen, Germany). The
optical density of each well was determined immediately using a
microplate reader set to 450 nm.
RT-qPCR
Cells were lysed for RNA extraction and subsequent qRT-PCR
analysis by adding 350 µl RA1 lysis buffer (Macherey-Nagel,
Düren, Germany) supplemented with 1% β-mercapto-ethanol
and stored at −80◦C. Total RNA was extracted using the
NucleoSpin RNA II Kit (Macherey-Nagel) as recommended by
the manufacturer. RT-qPCR was described elsewhere (Schmid
et al., 2015). The following primers were used: DENV2 (forward
5′-GCC CTT CTG TTC ACA CCA TT-3′; reverse 5′-CCA CAT
TTG GGC GTA AGA CT-3′); IFIT1 (forward 5′- GAA GCA
GGC AAT CAC AGA AA-3′; reverse 5′-TGA AAC CGA CCA
TAG TGG AA-3′). GAPDH mRNA (primer forward 5′ - GAA
GGT GAA GGT CGG AGT C−3′; reverse 5′ - GAA GAT
GGT GAT GGG ATT TC – 3′) was used for normalization of
input RNA.
Luciferase Assay
Cells were lysed in 100 µl Luciferase lysis buffer (1% Triton X-
100, 25mM glycyl-glycine, 15mM MgSO4, 4mM EGTA, and
1mMDTT, pH 7.8) and stored at−80◦C. For detection of Renilla
luciferase activity, 20µl lysate was mixed with 100µl assay buffer
(25mM glycyl-glycine, 15mMMgSO4, 4mM EGTA, and 15mM
potassium phosphate pH 7.8) containing 1.4µM coelenterazine
(P.J.K). All measurements were done in duplicate by using a
tube luminometer (Berthold, Pforzheim, Germany). Replication
efficiency was determined by normalization to the 2 h values
reflecting infection efficiency.
Mathematical Model
We developed a mechanistic mathematical model using ordinary
differential equations (ODEs) and mass action kinetics to analyze
the interplay between DV and the HIR. We have previously
published a detailed intracellular replication model for HCV
(Binder et al., 2013). Both DV and HCV are closely related
(+)RNA viruses of the same family, and their intracellular
replication proceeds in similar steps. We therefore used the
mathematical model of HCV replication as the basis for the
model structure of the current DV model. This model was
then extended to the full virus lifecycle by adding infection and
assembly of new virus particles to themodel.We then adapted the
model to DV where necessary (see details below), refitted model
parameters on the Huh7/DV infection data and complemented
the replication model by an HIR sub-model that comprises the
key components of the IIR. Figure 1 gives an overview of the DV
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replication sub-model and Figure 2 shows the HIR sub-model;
we describe each of the mainmodel components in the following.
DV Replication
Our DV replication sub-model (Figure 1) is composed of four
main processes in the DV lifecycle: (1) Binding of DV particles
to the cell surface and viral entry via endocytosis. (2) Uncoating
and release of the viral RNA genome into the cytoplasm, followed
by translation into a polyprotein that is subsequently cleaved
into the structural and non-structural viral proteins. (3) The
non-structural viral proteins initiate the formation of a RC,
in which the viral RNA replication takes place via a dsRNA
intermediate. (4) The newly synthesized (+)RNA can then be
used as a template for further RNA replication, for protein
production at the ribosomes, or it is used together with the
structural proteins to assemble new virus particles, which are
then released from the cell. The cycle thereafter starts over again
with further infection of naïve cells.
We model the infection process by the following three ODEs,
where V describes extracellular virus, VA is virus that has
attached to the host cell but is still at the cell surface, and VE is
virus that has been endocytosed:
dV
dt
= kreVINF − kaV − µVV − wV (1)
dVA
dt
= kaV − keVA (2)
dVE
dt
= keVA − kfVE − µVEVE (3)
FIGURE 1 | Graphical illustration of the DV replication model. (1) The Virus (V ) attaches to a permissive cell (ka) and (2) enters via receptor-mediated endocytosis (ke).
(3) The virus in the endosome (VE ) is degraded with rate (µVE ). The viral and endosomal membrane fuse (kf ) and release the viral RNA genome (RV ), which is degraded
with rate µRV . (4) Ribosomes (RiboDV ) bind (k1) at the viral RNA genome, forming a translation complex (TC), which in turn is degraded with rate µTC. (5) The viral
genome is translated (k2) into a long polyprotein (PP ) and (6) subsequently cleaved (kc) into structural (PS) and non-structural proteins (PN ), which degrade with rate
µPS and µPN , respectively. During the translation, luciferase (L) is produced as a marker for translation activity and is degraded with rate µL. (7) The TC together with
non-structural proteins and host factors (HF) initiating the formation (kPin) of a replication complex (RRC). (8) The antisense synthesis (k4m) leads to production of
double-stranded RNA (dsRNA) that (9) binds to non-structural proteins in the Replication Compartment RC (PRC) forming (k5) a minus-strand RNA intermediate
complex (RIDS). RIDS in turn (10) initiates plus-strand RNA synthesis (k4p). (11) The newly synthesized plus-strand RNA (RP ) can be exported out of the RC into the
cellular cytoplasm (kPout ), (12) undergoes another round of replication (k3) or (13) is packed into virus particles and released (kr ) from the host cell (14), where it can
infect naïve cells (kre) for a further round of replication. Species in the RC degrade with constant rate µRC, (15) except the dsRNA species which get transported out the
RC with rate constant µRC resulting in an accumulation of dsRNA in the cytoplasm (RR). Extracellular IFN and ISG proteins have an antiviral effect (AE⊣ see Figure 2)
on the DV lifecycle via different mechanisms (k1, kre, and µRV ) while the PN dependent countermeasures (VC⊣) targeting HIR pathways (krig and kjak , see Figure 2).
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FIGURE 2 | Graphical illustration of the HIR sub-model. (16) Upon recognition of cytoplasmic dsRNA (RR) via the RIG-I pathway (krig), IFN (FIN ) is produced that (17) is
released from the cell (ks). (18) Extracellular IFN (FEX ) activates the JAK/STAT pathway (kjak ) that leads to the production of ISG mRNA (IR). (19) Ribosomes (RiboHIR)
bind to ISG mRNA in order to form (kIC) a translation initiation complex (IC) that (20) translates (kt ) the ISG mRNA into ISG proteins (IP ). Extracellular IFN and ISG
proteins have an antiviral effect (AE⊣) on the DV lifecycle via different mechanisms (k1, kre, and µRV , see Figure 1) while the PN dependent countermeasures (VC⊣,
see Figure 1) targeting HIR pathways (krig and kjak ).
Equation (1) and (2) describe how extracellular virus (V) binds at
the cell surface of a permissive host cell with rate constant ka and
degrades with rate constant µV (Equation 1). To keep the model
simple, we assume that attachment is non-reversible. According
to the experimental set-up, the cells were washed to remove
unbound virus from the initial infection. This is considered in
the model through the term wV , where w is modeled as
w = ωs
1√
2πω2
d
e
−
(t−ωt)
2
2ω2
d , (4)
with washing time point ωt , washing duration ωd, and washing
strength ωs (for more details, see Supplementary Material).
The term kreVINF in Equation (1) describes newly released
infectious virus particles from previous rounds of virus
replication, which can infect naïve cells. Equations (2) and
(3) describe cell entry: Attached virus (VA) enters the cell
with rate constant ke via receptor-mediated endocytosis.
Subsequently, virus in the endosome (VE) undergoes
conformational changes of the nucleocapsid, leading to
fusion of the viral and endosomal membranes with rate
constant kf (Equation 3). Endocytosed virus VE decays with rate
constant µVE .
The steps associated with RNA translation are described
by the following ODEs, which are based on our previously
published HCV replication model (Binder et al., 2013). Here,
RV describes viral (+)RNA in the cytoplasm, TC corresponds
to active translation complexes, PP describes viral polyprotein,
and PS and PN are representatives for the structural and non-
structural viral proteins, respectively. In our experimental data,
PP is measured via a bicystronic luciferase reporter system,
the species L is therefore required for model fitting purposes
and gives luciferase protein concentration, which degrades with
rate constant µL. The following ODEs describe the temporal
evolution of these species:
dRV
dt
= kfVE − k1RV
(
RiboDVtot − TC
)
+ k2TC (5)
+kPoutRP − µRVRV
dTC
dt
= k1RV
(
RiboDVtot − TC
)
− k2TC (6)
− kPinPNTC
(
HFRC0 − RRC
)
− µTCTC
dPP
dt
= k2TC − kcPP (7)
dL
dt
= k2TC − µLL (8)
dPS
dt
= kcPP − µPSPs − NPS vp (9)
dPN
dt
= kcPP − kPinPNTC
(
HFRC0 − RRC
)
− µPNPN (10)
After cell entry, the viral RNA genome RV is released into the
cytoplasm and is subsequently translated giving rise to viral
protein or is degraded with rate constant µRV (Equation 5). Free
ribosomes (RiboDV ) reversibly bind to the viral RNA genome
(RV ) to form a translation initiation complex (TC, Equation
6) with rate constant k1. We assume that the total number of
ribosomes, RiboDVtot , is constant, hence free ribosomes available
for translation are given by RiboDV (t) = RiboDV0 − TC and
it is not necessary to introduce a separate equation for the
ribosomes. HFRC0 represents one or more unspecified host cell
factor(s) that are required for formation of the RC and is assumed
constant (see Table S1). Upon translation of the viral genome
into a polyprotein (PP, Equation 7) with rate constant k2, the
translation initiation complex (TC) dissociates into free viral
RNA (RV ) and ribosomes (RiboDV ). Furthermore, during TC
degradation with rate constant µTC, ribosomes dissociate from
the complex: RiboDV + RV → TC → RiboDV + RV +
PP + L. We measure polyprotein production using a luciferase
reporter system, and hence include luciferase (L, Equation 8)
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into the mathematical model. L is produced with rate constant
k2 and is degraded with rate constant µL. The polyprotein (PP)
is cleaved into structural (PS) and non-structural proteins (PN)
with rate constant kc, which degrade with rate constants µPS
and µPN , respectively. We note here further that later in the
virus lifecycle, the structural proteins (PS, Equation 9) are packed
together with newly synthesized (+)RNA (RP) into virions, thus
the corresponding term involving vp in equation (9), which is
detailed in equation (17) below. Furthermore, the non-structural
proteins (PN), e.g., the RNA-dependent-RNA polymerase, are
required for viral RNA synthesis (compare Equation 11).
Equations (11) to (16) describe the viral RNA replication
inside the replication vesicles. The species RRC describes
a replication intermediate complex for minus strand RNA
synthesis inside the RC, whereas RIDS is the corresponding
intermediate complex for (+)RNA production. RDS and RP
describe dsRNA and single (+)RNA in the RC. PRC corresponds
to the viral RNA polymerase in the RC that is required
for RNA replication. Replication is thus modeled by the
following equations:
dRRC
dt
= kPinPNTC
(
HFRC0 − RRC
)
− k4mRRC (11)
+k3RPPRC
(
HFRC0 − RRC
)
− µRCRRC
dRDS
dt
= k4mRRC − k5RDSPRC + k4pRIDS − µRCRDS (12)
dRIDS
dt
= k5RDSPRC − k4pRIDS − µRCRIDS (13)
dRR
dt
= µRC(RDS + RIDS)− µRVRR (14a)
dPRC
dt
= k4mRRC − k3RPPRC
(
HFRC0 − RRC
)
(15)
−k5RDSPRC + k4pRIDS − µRCPRC
dRP
dt
= k4pRIDS − k3RPPRC
(
HFRC0 − RRC
)
(16)
−kPoutRP − vp − µRCRP
By analogy to HCV, we assume here that the initiation of
RNA replication occurs from freshly translated viral RNA, hence
Equations (6) and (11) model RNA import into the RC from
TC (instead of RV ) with rate constant kPin. At the same time,
non-structural proteins (PN), required for RNA synthesis, and
an unspecified host factor HFRC, required for the formation of
the RC, are imported into the RC. These assumptions directly
match those made in our published HCV replication model
(Binder et al., 2013). As the total amount of host factor HFRC is
assumed constant during the time scales considered in themodel,
a separate equation for HFRC is not necessary. We furthermore
note that, while numerous replication vesicles can be observed
during DV replication in every single cell (Welsch et al., 2009),
we assume in the model that the sum of all replication vesicles
is regarded as a single, large replication compartment, compare
(Dahari et al., 2007).
After formation of the replication initiation complex RRC,
minus-strand RNA synthesis is initiated with rate constant
k4m, leading to the production of dsRNA (RDS, Equation 12)
and liberation of viral proteins which remain in the RC (PRC,
Equation 15). For the synthesis of (+)RNA (RP, Equation 16),
dsRNA (RDS) binds again to PRC with constant rate k5 in order to
form a minus-strand RNA intermediate complex (RIDS, Equation
13). The minus-strand RNA intermediate complex (RIDS) serves
as a template for (+)RNA synthesis with constant rate k4p and
subsequently dissociates into dsRNA (RDS) and viral protein
(PRC). The newly synthesized (+)RNA (RP) can then either be
transported out of the RC into the cytoplasm with rate constant
kPout , it can be used for a further round of replication with rate
constant k3, or it is used to assemble new virions, which are then
released from the cell (vp). We assume that all species in the RC
are protected from active degradation, and decay together with
the membrane vesicles with a common rate constant µRC.
Since the RCs might represent a protective environment
for DV replication by shielding DV RNA from the host’s
immune response recognition (Scutigliani and Kikkert, 2017),
we introduced a cytosolic dsRNA species (RR, Equation 14a).
Therefore, for the dsRNA species within the RC, RDS and
RIDS, µRC represents a transfer rate into the cytoplasm and
leads to the accumulation of cytosolic dsRNA that is detectable
by the innate immune sensor (Chazal et al., 2018), while the
RNA species within the RC remain protected. In order to
account for a slow transfer rate without introducing another
model parameter, we use the RNA degradation rate inside the
replication compartment, µRC, for this purpose. Similar to the
single stranded RNA species within the cytoplasm, the cytosolic
dsRNA degrades with rate µRV .
Finally, Equations (17) to (19) model the assembly and
release of new virus particles. To produce one infectious virion,
the newly synthesized (+)RNA (RP) assembles together with
structural proteins: 180C proteins, 180 E, and 180 prM/M
proteins (Kuhn et al., 2002). Moreover, it has been shown that
non-structural proteins support DV particle production as well,
e.g., DVNS1 (Scaturro et al., 2015). However, we observed during
model fitting that non-structural proteins were not rate limiting
for virus assembly and therefore we neglected PN in the assembly
process, while we focused on structural proteins and host factors
required or participating in virus assembly and release (for more
information see Supplementary Material).
We model DV assembly and release (vp) using a Michaelis-
Menten type equation, as
vp = kpRP
∏
j
Pj
KD · NPj + Pj
, (17)
with j ∈ {PS,HFPP}, NPj the number of each protein Pj, and cell
line-specific virion release rate constant kp, compare (Heldt et al.,
2012). We require here that sufficient proteins per virion need
to be available in order to reach the half-maximal virion release
rate KD. Furthermore, we introduced a second host factor HFPP
for particle production, with a cell line-specific basal production
rate kHFPP :
dHFPP
dt
= kHFPP − NHFPP vp. (18)
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The infectious virions (VINF) are released from the cell and are
then able to infect naïve cells with a reinfection rate constant kre
(Equation 19); they furthermore are assumed to degrade with rate
constant µV , thus
dVINF
dt
= vp − kreVINF − µVVINF . (19)
Host Cell Immune Response
We coupled the replication model with a simple model
containing the central steps of the cell’s IIR to infection. This
HIR sub-model (Figure 2) comprises four main processes: (1)
The recognition of viral RNA by cellular PRRs, leading to the
initiation of a signaling cascade that causes (2) the production
and release of IFN. (3) Subsequently, secreted IFN triggers the
transcription of mRNAs of hundreds of ISG, which are then (4)
translated into ISG proteins that act upon multiple processes in
the DV lifecycle. To keep the model simple, we subsume the
different ISGs by a single representative species, included in the
model by its mRNA (IR) and protein (IP) species.
As mentioned above and to keep the model simple, we include
only dsRNA recognition via RIG-I/MDA-5 into the model. As
soon as dsRNA is detectable in the cytoplasm, it activates the
HIR. We therefore modified the equation for RR (Equation 14a)
as follows (changes in bold), where krig describes the rate at
which the RIG-I pathway is activated and IFN is produced when
cytoplasmic RR is bound by the receptor:
dRR
dt
= µRC (RDS + RIDS)− µRVRR − krigRR. (14b)
The dynamics of key components of the HIR, namely
intracellular IFN (FIN), secreted IFN (FEX), ISG mRNA (IR), and
ISG protein (IP) are given by the following ODEs:
dFIN
dt
= krigRR − ksFIN − µFFIN , (20)
dFEX
dt
= ksFIN − kjakFEX − µFFEX , (21)
dIR
dt
= kjakFex − kICIR
(
RiboHIRtot − IC
)
+ ktIC
−µIR IR, (22)
dIC
dt
= kICIR
(
RiboHIRtot − IC
)
− ktIC − µICIC, (23)
dIP
dt
= ktIC − µIP IP. (24)
Here, upon recognition of cytoplasmic dsRNA (RR, Equation
14b), the cell produces IFN (FIN , Equation 20) via the RIG-
I/MDA-5 pathway with rate constant krig . IFN either degrades
with rate constant µF or is secreted from the cell (FEX , Equation
21) with rate constant ks and then degrades extracellularly with
rate constant µF . Extracellularly, FEX binds to receptors that
activate the JAK/STAT pathway, we assume this to happen
with rate constant kjak. Activation of the JAK/STAT pathway
then triggers the production of ISG mRNAs (IR, Equation 22),
which we assume to degrade with rate constant µIR . Ribosomes
(RiboHIR) bind to IR to form a translation initiation complex (IC,
Equation 23) with rate constant kIC, which in turn degrades with
rate constant µIC. The subsequent translation of the translation
initiation complex (IC) with rate constant kt leads to the
production of ISG proteins (IP, Equation 24). We assume that IP
degrades with rate constantµIP . Similar to TC, IC dissociates into
RiboHIR and IR (IR + RiboHIR → IC → IP + IR + RiboHIR). Note
that in order to prevent ribosomal competition in the model, we
discriminate between ribosomes used for DV RNA translation
(RiboDV ) and ribosomes used for the HIR (RiboHIR).
The ISG proteins (IP) affect numerous processes in the viral
lifecycle. Here we focus on effects it has on the formation of the
translation initiation complex (k1) and the degradation of viral
RNA in the cytoplasm (µRV ) (Diamond, 2014; Castillo Ramirez
and Urcuqui-Inchima, 2015). We furthermore assume that the
ISGs cannot reach species inside of the replication vesicles, which
thus provides a protected environment for viral replication (see
Supplementary Material for details). We include these effects
into the model by decreasing the corresponding reaction rate
constant k1 to
k̂1 =
k1
1+ εk1 IP
, (25)
and increasing the degradation rate µRV to
µ̂RV = µRV (1+ εµRV IP). (26)
Furthermore, we take into account that IFN released from
infected cells can protect naïve cells from infection by bringing
them into an antiviral state, this has been integrated into the
model by decreasing the corresponding reaction rate constant
kre to
k̂re =
kre
1+ εkreFEX
. (27)
The efficacy constants ε∗ measures the efficacy of the inhibition
on a range from 0 (no effect) to 1 (full inhibition).
Viral Countermeasures
DV is not only subjected to theHIR, but viral proteins in turn also
impair the host’s immune response, thus constituting a negative
feedback loop of mutual inhibition. Several viral proteins have
been described inhibiting HIR pathway activation. For example,
DV NS3, NS4A, and NS5 inhibit the RIG-I pathway activation
by the methylation of the DV RNA (DV NS5) or by blocking
the RIG-I/MAVS interaction (DV NS4A) (Chazal et al., 2018).
Additionally, by promoting the degradation of STAT2, DV NS5
impairs activation of the JAK/STAT pathway and thus ultimately
inhibits ISG production upon exposure of the cell to exogenous
IFN (Ashour et al., 2009; Mazzon et al., 2009). Therefore, we
incorporated the ability of DV to circumvent the HIR in two
ways (ĉx): (i) by reducing the reaction rate of the RIG-I pathway
activation that may lead to a decreased IFN production (krig), and
(ii) by decreasing the reaction rate for the JAK/STAT pathway
activation that may result in a decreased ISG expression (kjak).
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Similarly, to the antiviral HIR effect, we incorporated these viral
countermeasure effects into our model
ĉx =
cx
1+ εxPN
, (28)
with cx ∈ {krig , kjak} and its efficiency constant εx ∈ [10−5, 1],
dependent on DV non-structural protein concentration. Hence,
we replaced the rate constants krig and kjak in equations (14b),
(20), (21), and (22) by the terms k̂rig and k̂jak as defined above
(see Supplementary Material for details).
Parameter Estimation
We implemented the mathematical model in Matlab Release
2016b (The Mathworks). Twenty out of the total 56 model
parameters were fixed based on evidence from literature, direct
calculations or observations made during the optimization
process, see Tables S6, S7. In brief, since infection experiments
were carried out at a multiplicity of infection (MOI) of 10 and
assuming that the fraction of infected cells follows a Poisson
distribution (Flint et al., 2009; Wulff et al., 2012), we computed
an initial virus concentration of V0 = 10 infectious virus
particles per ml per cell. Washing of cells to remove unbound
virus was performed thrice after 1 h for a duration of 6min,
we therefore set ωt = 1 h, ωd = 0.1 h and assume a
washing strength of ωs = 100. Model parameters for translation
and replication rates were estimated based on the DV genome
length of approximately 10,700 nucleotides and DV polyprotein
length of 3,400 amino acids. During the fitting process, we
observed no difference whether the ribosomes bind to viral RNA
(RV ) or host cell mRNA (IR) and set k1 = kIC. Assuming a
translation velocity of 3 to 8 AA/s per polysome and assuming
10 ribosomes bound to each 2,000 AA (Dahari et al., 2009),
we obtain k2 = 100 h−1. The translation rate (kt) for the
ISG proteins (IP) was calculated accordingly as kt = 120 h−1,
using the IFIT1 protein as a representative ISG with a length
of 478 AA (Safran et al., 2010). RNA synthesis rate constants
were calculated as k4m = k4p = 1.01 h−1, using a transcription
rate of 180 nt per min (Dahari et al., 2009). Degradation rates
for extracellular virus and IFN were set to µV = 0.4 h−1 and
µF = 0.15 h−1 (Schmid et al., 2015). Note that for simplicity,
we assumed that the intracellular IFN degradation equals the
extracellular degradation, µF . We observed a higher stability of
virus within endosomes (µVE ) compared to extracellular virus
(µV ) and fixed the degradation rate of virus within endosomes
to µVE = 0.5 · µV . The degradation rate for luciferase µL =
0.35 h−1 as well as the polyprotein cleavage rate kc = 1 h−1
were taken from our HCV replication model (Binder et al.,
2013). The translation initial complexes TC and IC are assumed
to be more stable than free cytosolic DV RNA genome (RV )
and ISG mRNA (IR) due to the bound ribosomes. Therefore,
the degradation rates µTC and µIC are assumed to be lower
than the degradation rates µRV and µIR . The degradation rate
for ISG proteins was fixed to µIP = 0.03 h
−1, corresponding
to a half-life of t1/2 = 24 h based on literature showing
half-lives for ISG proteins in the range of 12 h and 2.3 days
(Ronni et al., 1993; Martensen and Justesen, 2004; Haller et al.,
2007; Bogunovic et al., 2013). The half-maximal virion release
rate (KD) needed for the virus assembly and release term (vp)
was approximated based on the experimental measurements of
extracellular virus particles. Here, we calculated that in Huh7
cells, KD = 1.8 virions/ml per measurement time point
were produced, while in A549 cells, KD = 0.7 virions/ml
per measurement time point were produced. The number of
structural proteins required to produce one virion has been
taken from literature with NPS = 180 molecules/virion (Kuhn
et al., 2002). During the fitting process, we observed a 10 times
higher basal production rate for the host factor involved in
assembly/release in Huh7 cells than in A459 cells. We therefore
set kHuh7HFPP = 10 · k
A549
HFPP
. Furthermore, we observed that the
initial concentration of the cell line specific host factor involved
in virus assembly and release was fitted to the same value and
thus set HFHuh7PP0 = HF
A549
PP0
= HFPP0 . However, we assume that
the initial host factor (HFRC0 , HFPP0 ) and ribosome (RiboDV0 ,
RiboHIR0 ) concentrations, as well as the number of consumed
host factors in the virus assembly and release process (NHFPP ) are
≥ 1molecules/virion. The antiviral HIR and DV countermeasure
efficiency constants were estimated within ε∗ ∈ [10−5, 1],
while the remaining model parameters have been estimated
within the range
[
10−5, 103
]
. Initial specie concentrations were
VA0 = VE0 = VINF0 = 0 virions/ml for virus species,
RV0 = TC0 = RRC0 = RDS0 = RIDS0 = RR0 = RP =
PP0 = PS0 = PN0 = L0 = PRC0 = 0 molecules/ml for
viral RNA, protein and luciferase species and FIN0 = FEX0 =
IR0 = IC0 = IP0 = 0 molecules/ml for the IFN and ISG
species, while the initial concentrations of host factors (HFRC0 6=
HFPP0 6= 0molecules/ml) and ribosomes (RiboDV0 6= RiboHIR0 6=
0 molecules/ml) have been estimated (for more details, see
Supplementary Material).
To fit the model to the experimental data, we computed
RtotP = (VE + RV + TC + RRC + RDS + RIDS + RR + RP),
V tot = (V + VA + VINF), and ItotR = (IR + IC) and introduced
four scaling factors fScaleL, fScaleR, fScaleF , and fScaleIR to
rescale experimental measurements acquired in relative values
(Luciferase, DV RNA, and ISG mRNA) and pg/ml (IFN).
Remaining free model parameters were then estimated from the
experimental data. Parameter estimation was performed using
the Data2Dynamics Matlab toolbox (Raue et al., 2015), using a
deterministic trust region algorithm (lsqnonlin) with Latin hyper
cube multi-start, minimizing the log likelihood function (Raue
et al., 2013) (for more details see Supplementary Material).
Parameter estimation was performed simultaneously for the
Huh7 and A549 cell lines, where only the DV replication sub-
model was used in the Huh7 cells and the full model including
the immune response sub-model in the A549 cell line. The only
other parameters that were allowed to vary between the two cell
lines were the initial concentrations of the host factor for the
formation of the minus-strand synthesis complex (HFRC0 ) as well
as the basal production (kHFPP ) of the host factor for particle
production (HFPP0 ). It is likely that more processes are cell line
specific, however, here we summarized all model parameters
that did not show any impact on the model fit and focused
mainly on cell line specific host factor availability andHIR effects.
Tables S6, S7 summarize the final, resulting model parameters
used after model fitting.
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Model Analysis
Simulation of Antiviral Intervention
We used the model to study potential antiviral strategies. For
this purpose, we extended the model by effects of direct-acting
antiviral drugs (DAAs). A drug efficacy parameter 0 ≤ ε ≤ 1 was
introduced to simulate drug effects on viral attachment (ka), viral
entry (ke), formation of the translation initiation complex (k1),
translation (k2), polyprotein cleavage (kc), replication complex
formation (kPin), minus- and (+)RNA synthesis (k4m and k4p),
virus particle production and release (vp), and infection of naïve
cells (kre), by multiplying the corresponding parameter with (1−
ε). We then calculated the time-averaged infectious virus particle
concentration released from the cell upon drug administration
(ε > 0) within a time interval of 5 days (1t = 120 h), normalized
to the time-averaged infectious virus concentration without drug
treatment (ε = 0) as
ψ =
〈
VINF (t)Tε>0
〉
〈
VINF (t)Tε=0
〉 , (29)
with
〈VINF (t)T〉 =
1
1t
∫ T+1t
t
dtVINF (t), (30)
where T refers to the time point of drug administration (T ≤ t ≤
T +1 t).
Identifiability and Sensitivity Analysis
We assessed model identifiability using the profile likelihood
method, which analyzes both structural and practical
identifiability. The profile likelihood method evaluates the
change in the likelihood function after modification of one
individual model parameter by re-optimizing the remaining
model parameters (Raue et al., 2009; Kreutz et al., 2013; Maiwald
et al., 2016), thus assessing if changes in a given parameter can be
compensated by modifications in other model parameters. Based
on the profile likelihood, we calculated 95% confidence intervals
on model parameters, which imply parameter identifiability if
the confidence interval is finite (Raue et al., 2009, 2015). Local
and global sensitivity analysis were carried out in Matlab using
the SensSB toolbox (Rodriguez-Fernandez and Banga, 2010)
and the extended Fourier Amplitude Sensitivity Test (eFAST)
(Marino et al., 2008). Sensitivities with regard to polyprotein
(PP), total (+)RNA (RtotP ) and total Virus (V
tot) concentrations
were calculated for the two time points t = 4 hpi (early during
infection) and t = 72 hpi (at steady state).
RESULTS
In order to in silico analyze the full DV lifecycle in the absence
and presence of HIR mechanisms, we developed a detailed
model of the intracellular DV lifecycle and coupled this model
to an HIR model, taking into account the antiviral effect of an
active immune response on the DV lifecycle as well as DV’s
ability to in return attenuate the HIR (Figures 1, 2). Model
calibration was performed by estimating model parameters
simultaneously on experimental data measured in two different
cell lines, Huh7 and A549 cells (for details see Materials and
Methods). For this purpose, we measured viral polyprotein
(luciferase readout), (+)RNA, extracellular virus, and IFN in
both cell lines, while ISG mRNA was measured only in A549
cells, as the Huh7 cell do not show activation of the interferon
system after DV infection. Polyprotein (luciferase) showed a
1-log10 higher translation activity in Huh7 cells compared to
A549 cells (Figure 3A). Similarly, Huh7 cells showed a higher
extracellular infectious virus concentration compared to A549
cells (Figure 3C). However, in both cell lines, the extracellular
virus concentration drops after reaching a peak (∼32 hpi in Huh7
and 36 hpi in A549 cells). Nevertheless, against our expectations,
DV (+)RNA measurements showed the opposite trend with a
faster RNA production in A549 cells (Figure 3B). Additionally,
IFN has been measured in both cell lines and showed an increase
in secreted IFN in A549 cells (which is followed by ISG mRNA)
and a baseline IFN level in Huh7 cells (Figures 3D,E).
Our coupled model, developed based on best biological
knowledge, showed high agreement with our experimental cell-
line specific measurements after fitting model parameters to the
data (Figure 3). Due to the high degree of freedom of the model
and in order to prevent overfitting, we analyzed structural and
practical identifiability of model parameters. Results are shown
in Figure S12; as can be seen in the figure, due to the high
model complexity, not all model parameters are identifiable. In
particular the parameters for replication within the RC (k3) and
DV RNA export out of the RC (kPout) are non-identifiable. Both
parameters concern the use of newly synthesized plus-strand
RNA and reflect the allocation of such newly synthesized RNA to
either further rounds of RNA replication (k3) or to export from
the replication compartment and use for protein translation. The
fact that these two parameters are non-identifiable is surprising
at first, as allocation of newly synthesized RNA between these
processes should significantly affect viral replication dynamics.
However, this can be explained by other processes that are rate-
limiting. In fact, we observed a similar behavior in our HCV
replication model (Binder et al., 2013), where in high permissive
cell lines the HCV RNA-dependent RNA polymerase became in
fact rate limiting for RNA replication inside of the replication
vesicles, and led to a similar insensitivity of the model to the
parameter k3. This is reflected in DV as well, with only limited
impact of parameters k3 and kPout on the replication dynamics in
both cell lines.
Host Dependency and Restriction Factors
The first question we addressed was cell line specificity. In
contrast to our expectations, we observed a faster onset and
more efficient viral replication in the HIR-competent A549
cells. Here, our model was not able to describe the DV RNA
dynamics in A549 cells that seemed unaffected by the HIR
and showed a faster increase and an overall 2.7-fold higher
amount of DV RNA (time-averaged concentration) compared
to Huh7 cells. Viruses strongly depend on their living hosts
and hijack host cell membranes, proteins, and lipids for
their own replication. We thus speculated that other host
processes explain this difference between the two cell lines.
We tested different such potential host factors by including
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FIGURE 3 | Best model fit of the DV replication model (Huh7) and the coupled model (A549) compared to experimental data measured in Huh7 and A549 cells (for
parameter values see Tables S6, S7). Experimental measurements are represented as mean µ± standard deviation σ . The DV replication model and the coupled
model were fitted simultaneously to the Huh7 and A549 data sets with cell line specific differences mediated by host factors, the antiviral HIR effect, and DV
countermeasures (Equations 1 to 28). (A) shows the model fit of luciferase compared to the luciferase measurements (L = Luc), (B) model fit of total (+)RNA to the
(+)RNA measurements (RtotP = (+)RNA), (C) model fit of extracellular virus to its measurements (V
tot = Virus), (D) model fit compared to measurements of the HIR
(ItotR = ISG mRNA and FEX = extracellular IFN), while (E) shows the model prediction of the coupled model with cell line specific Huh7 parameter values and the
knocked-out RIG-I pathway activation krig = 0 h
−1 compared to IFN measured in Huh7 cells.
corresponding cell-line specific parameters into the model,
compare Table S3, and discriminated between these models
using model selection based on Aikaike’s Information Criterion
(AIC). In line with our previous findings with our published
HCV model (Binder et al., 2013), we introduced an unspecific
cell line specific host factor, HFRC, that participates in the
assembly of the replication complex and RC formation. In
model fitting, this host factor showed a higher availability
leading to a faster onset of DV replication in A549 cells
compared to Huh7 cells (Table S6). We furthermore tested
cell-line specific effects on different host factor supported
processes such as virus entry, that improved the overall model fit
without explaining the cell line specific DV RNA dynamics (see
Table S3).
We additionally observed a cell line specific variation in
the extracellular DV dynamics, resulting in a 2.8-fold lower
extracellular virus concentration (time-averaged) in A549 cells,
that could not be described by the HIR alone. Thus, we
introduced another unspecific host factor,HFPP, involved in virus
particle production and release, with a cell line specific basal
production, kHFPP , and a cell line specific virus assembly and
release rate, kp. During model parameter estimation, we observed
a faster virus assembly and release and an around 10 times faster
basal production of the host factor involved in DV assembly
and release in Huh7 cells compared to A549 cells. This basal
host factor production was the key parameter for the lower virus
concentration in A549 cells in steady state. Furthermore, this
host factor represented a limiting species for particle production
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FIGURE 4 | Percentage increase and decrease of model parameters of the antiviral (k̂1, k̂re, µ̂RV ) and countermeasure (k̂rig, k̂jak ) effect of the HIR and DV on model
parameters as a function of time (Equations 25 to 28; Table 1). The antiviral HIR mediated inhibition of the (A) translation initiation complex formation k1, (B) naïve cell
infection/reinfection kre, (C) cytosolic DV RNA degradation. The DV mediated countermeasure of (D) RIG-I pathway krig and (E) JAK/STAT pathway kjak , as well as (F)
the ISG protein concentration over time. Note that k̂1 and µ̂RV are ISG dependent, while k̂re is IFN dependent.
and release, since the drop in the extracellular DV concentration
following the peak was associated with a drop in the host factor
concentration. Interestingly, the availability of structural proteins
had no effect on the drop in released virus (see Figure S1).
The Antiviral HIR Effect and Viral
Countermeasures
During an acute infection, the IIR represents the first line of
defense against an invading pathogen. The IIR is mounted by
the production of IFN and subsequent ISG translation; the ISGs
in turn subsequently inhibit multiple steps in the viral lifecycle.
Having developed a detailed model coupling the DV lifecycle
with key players of the HIR, we studied the antiviral modes of
action in detail and introduced three possible antiviral HIR effects
on (i) the translation initiation (k1), (ii) the degradation of free
cytosolic DV RNA (µRV ), and (iii) the reinfection of naïve cells
(kre) into the model. Selection of these three main mechanisms
was based on model selection using the least squared error with
the AIC to account for model complexity. For details we refer
to the Supplementary Material. By comparing the model fits
and its AICs, we observed the best model fit and lowest AIC
for a model in which the HIR inhibits the translation initiation
complex formation (k1), followed by a model, that increases
the degradation of free cytosolic viral RNA (µRV ). However,
the model considering only the increase in the cytosolic RNA
degradation (µRV ) resulted in a very high cytosolic DV RNA
degradation rate of µ̂RV = 987 h
−1. The model that led to an
antiviral state by inhibiting reinfection of naïve cell infection led
to the third best model. Since we are interested in combinatory
effects, we chose all three antiviral ISG and IFN dependent effects
as our working model.
In the combined HIR effect model, the inhibition of the
translation initiation (k1) and the reinfection of susceptible cells
(kre) by the HIR showed the highest efficacy constants with
εk1 = εkre = 1 (Table S7). Comparing the inhibitory effect
on the effective rate constants over time, the rate constant
for k1 dropped by 99.983% from its initial value, while kre
showed a negligible 1.6% decrease (Figure 4 and Table 1). The
cytoplasmic RNA degradation rate was increased by 58.7%. DV
has the ability to evade the HIR by decreasing or inhibiting its
own recognition, correspondingly, the rate constants for RIG-
I pathway activation and dsRNA recognition was reduced by
93.6%, while the JAK/STAT pathway activation was reduced by
88.6% (Table 1).
Frontiers in Microbiology | www.frontiersin.org 11 April 2020 | Volume 11 | Article 725
Zitzmann et al. Modeling Dengue Virus Replication
TABLE 1 | Effect of the immune response on DV replication parameters and of
Dengue on parameters of the immune pathways—change in parameter values
over 100 h for HIR affected processes in the DV lifecycle and HIR pathways that
are targeted by DV: Translation initiation complex formation (k1), naïve cell
infection/reinfection (kre), cytosolic RNA degradation (µRV ), RIG-I pathway (krig ),
and JAK/STAT pathway (kjak ).
Parameter t= 0 h t= 100 h Unit Increase/Decrease in %
k1 1,000 0.17 ml molecules
−1 h−1 −99.983%
kre 1e-4 9.8e-5 h
−1 −1.6%
µRV
2.8 4.4 h−1 +58.7%
krig 2.6 0.2 h
−1 −93.6%
kjak 100 11.4 h
−1 −88.6%
In order to further mathematically analyze the interplay of
antiviral effects (krig and kjak) and the viral ability to attenuate
the HIR (εkrig and εkjak ), we performed a bifurcation analysis
at time 72 hpi. Here, we compared the (+)RNA concentration
to various effect combinations: (i) the recognition of DV
dsRNA (krig) vs. DV’s ability to attenuate its own recognition
(εkrig ) and (ii) the activation of the JAK/STAT pathway (kjak)
vs. DV countermeasures targeting the JAK/STAT pathway
(εkjak ) (Figure 5). In the first scenario, we observed a clear
separation: with increasing krig the HIR wins and the infection
is effectively cleared with only minimal residual (+)RNA, while
with increasing εkrig the virus wins and the infection is ongoing.
In contrast, in the second scenario we found that increasing the
activation of the JAK/STAT signaling pathway (kjak) did not lead
to significant decreases in viral RNA levels.
Antiviral Drug Intervention
We were further interested in using the mathematical model to
identify processes with a high impact on the DV lifecycle, as those
might constitute attractive targets for antiviral drug development.
For this purpose, we performed a global sensitivity analysis to
analyze the effect of all model parameters on viral polyprotein,
total DV (+)RNA and extracellular virus concentrations at two
distinct time points, 4 and 72 hpi (Figures 6, 7).
Both cell lines showed a comparable sensitivity profile for
polyprotein, DV (+)RNA, and the extracellular virus and showed
high sensitivities to processes associated with cell infection,
polyprotein translation and processing, and DV RNA synthesis.
For all the three species, early processes in the viral lifecycle
were associated with highly significant sensitivities at 4 hpi,
such as virus attachment (ka), entry (ke), and fusion (kf ),
as well as polyprotein translation (k2). Later in infection (72
hpi), ongoing polyprotein translation as well as processes
within the RC dominated in their sensitivities for the three
studied species. Especially polyprotein cleavage (kc) became the
dominant process with the highest impact of all steps involved
in viral protein translation. Of the processes occurring inside
of the RC, the most sensitive rate constants were associated
with RNA synthesis (k4m, k4p) and the host factor involved in
the formation of the RC (HFRC) for both cell lines. For the
extracellular virus, the number of host factors (NHFPP ) involved
in assembly and release showed a higher sensitivity compared
FIGURE 5 | Plus-strand RNA concentration for various model parameter
combinations for: (A) the antiviral RIG-I pathway activation (krig) vs. the viral
countermeasure targeting the RIG-I pathway (εkrig ) and (B) the JAK/STAT
pathway activation (kjak ) vs. its viral counteract (εkjak ). The black lines represent
the model parameter combinations that have been estimated from the data
(Table S7).
to the number of viral structural proteins (NPS ). Amongst the
HIR model parameters, the RIG-I pathway activation (krig)
showed a slightly higher, significant sensitivity on the polyprotein
species. Furthermore, the HIR efficacy constant decreasing the
rate constant of the naïve cell infection (εµRV ) showed the highest
sensitivity of all antiviral HIR constants, albeit not reaching
statistical significance.
As a next step, we were interested in the question whether
the highly sensitive processes identified in the previous analysis
might represent potent drug targets. We therefore performed a
theoretical antiviral intervention by simulating a possible drug
administration. In this simulation, we monitored the release
of infectious virus for 5 days following drug administration.
Several processes in the DV lifecycle were inhibited by simulated
drug administration at 0 hpi, 24 hpi, and 72 hpi (Figure 8).
An early drug administration at 0 hpi led to an efficient viral
clearance in both cell lines, using a hypothetical drug acting on
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any process in the DV lifecycle except for putative drugs targeting
reinfection. With the support from the HIR, the overall drug
efficacy constants necessary to eradicate the virus in A549 cells
were lower. In particular drugs targeting translation initiation
and the DV RNA synthesis were able to induce viral clearance
even with low drug efficacy constants, and administering a drug
targeting the DV RNA synthesis process showed a viral clearance
with the lowest drug efficacy constant (ε ≈ 0.5) in A549 cells. For
drugs targeting any one of the remaining processes, drug efficacy
constants higher than ε ≥ 0.9 were needed to clear the viral
infection. Administering a hypothetical drug at 24 and 72 hpi
led to comparable viral clearance patterns, but with higher drug
efficacy constants. Obviously, if a drug is administered late in the
viral lifecycle and targets early processes of the viral lifecycle such
as virus attachment, endocytosis and fusion as well as formation
of the (membranous) replication compartment, leads to a loss of
the drug effect and non-clearance of the DV infection in both
cell lines. In both cell lines, the DV infection can still be cleared
when blocking DV RNA synthesis and virus assembly/release
with <3% DV left with the highest drug efficacy of 1 (thus
completely shutting of RNA synthesis and assembly/release),
an outcome which cannot be achieved by targeting any of
the other processes in the DV lifecycle according to our
model simulations.
DISCUSSION
In the present study, we investigated the intracellular virus
replication and HIR dynamics in two different cell lines: Huh7
cells with very low HIR-competence and highly HIR-competent
A549 cells. Several cell population models have been developed
to analyze DV dynamics under influence of the innate (Schmid
et al., 2015) and the adaptive immune response (Ben-Shachar
and Koelle, 2014; Clapham et al., 2014, 2016; Ben-Shachar et al.,
2016). These models, however, do not take intracellular processes
into account and thus lack molecular detail. In order to study
the intracellular dynamics during the DV lifecycle, we developed
the first mathematical model that reflects the initial dynamics of
key components of the intracellular DV genome replication. Our
detailed model is derived from previous mathematical models
that have been used to describe the intracellular RNA replication
of a HCV replicon system after RNA transfection (Dahari et al.,
2007; Binder et al., 2013).We extended these models by including
virus entry and release of infectious virus particles. Furthermore,
we coupled the virus dynamics model to a model of the HIR
activation and effector phases in order to study the modes of
action of the HIR, and to analyze potential antiviral intervention
strategies acting at the level of intracellular mechanisms.
Host Factors
Our experimental measurements were performed in two different
cell lines: Huh7 cells which show no interferon response, and
A549 cells showing a strong immune reaction. However, Huh7
cells are based on hepatoma (liver) cells, whereas A549 cells
are of pulmonary epithelial origin, thus they likely differ in
several other aspects as well. In fact, some characteristics of
our experimental data cannot be explained by the lack of an
interferon response in the Huh7 cells alone. Contrary to our
expectations, we observed a faster onset and more efficient
DV genome replication in the immuno-competent A549 cells.
We therefore tested which other host factors may explain
such cell line specific differences. We set up several different
models for such host factors, fitted the corresponding models
to the experimental data, and compared different models using
AIC; details are given in the Supplementary Material. In our
previous HCV study, we have shown that host factors involved
in replication complex formation play a crucial role in cell
permissiveness and viral replication efficiency (Binder et al.,
2013). Similarly, for DV, such a host factor best explained
differences in replication efficiency between the two cell lines.
According to our model, the more efficient RNA replication
(earlier increase and a higher steady state concentration of total
(+)RNA in the A549 cell line) is directly associated with a higher
concentration of this putative host factor in A549 cells, similar
to our previous results considering HCV replication in different
Huh7 cell clones (Binder et al., 2013).
Concerning the extracellular virus dynamics, our model
was not able to explain the drop in infectious virus titers
observed in the experimental data after ∼40 h post infection—
at different degrees in both cell lines—by a limitation in
structural viral proteins. In fact, our simulation results show
that structural proteins do not limit the process of particle
production and release. Similar to our finding, Heldt et al. (2012)
in a mathematical model of influenza A virus replication did
not find a limitation in structural proteins and suggested that
transport and budding processesmight limit the viral production.
Furthermore, the drop in virus titers that we observed in our
data is qualitatively present in both cell lines, i.e., in the presence
and in the absence of the HIR, it is therefore unlikely that
it is due to effects of the HIR on virus assembly and release.
Therefore, we integrated another unspecific host factor, HFPP,
that is involved in virion assembly, maturation, and release into
the mathematical model with a cell line-specific basal host factor
production and a cell line specific virus assembly and release rate.
Fitting of this extended model resulted in a higher production
rate of this assembly/release host factor in Huh7 cells, explaining
the higher viral steady state level in these cells. Several host
factors affecting DV assembly / release are known; we recently
employed siRNA screening to identify such factors and described
a mechanisms involving Fibroblast Growth Factor Receptor 4
(FGFR4), a host factor supporting DV RNA replication when
FGFR4 concentration is high, but leading to increased assembly
andmaturation of virus particles when this host factor is depleted
(Cortese et al., 2019). While FGFR4 is one potential mechanism,
the exact identity and mechanisms of host factors differences
between A459 and Huh7 based cell lines needs more exploration
in the future.
DV and the HIR
We next employed our mathematical model to characterize the
interplay between virus replication on the on hand and the HIR
on the other. During DV infection, activation of the interferon
system leads to the transcription of hundreds of antiviral ISG
proteins at different time points, with effects on multiple steps in
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FIGURE 6 | Global Sensitivity analysis performed for the DV replication model for polyprotein (A,B), (+)RNA (C,D), and extracellular virus (E,F), as well as for two
different time points: 4 hpi (A,C,E) and 72 hpi (B,D,F). The red line is a negative control used for the sensitivity analysis that is not part of the model indicating that
sensitivities below the red line are negligible. Significant differences to the negative control have been calculated by performing a t-test (p-values: *** ≤ 0.001, ** ≤
0.01, * ≤ 0.05).
the viral lifecycle. In case of HCV, which is closely related to DV
and one of the best studied (+)RNA viruses, ISG proteins have
been identified to act on almost every step in the HCV replication
cycle (Schoggins and Rice, 2011; Metz et al., 2013; Gokhale
et al., 2014). Integrating such a multitude of mechanisms into a
mathematical model is therefore a daunting task. To keep things
simple, we tested different potential antiviral ISG mechanisms
individually by including them into our mathematical model
and retained the combination of mechanisms leading to the
lowest AIC values in model comparison. As we assumed that
the intracellular RC protects the newly synthesized viral RNA
from detection by and effector mechanisms of the HIR, we did
not include any ISG effects on species inside of the RC in our
model (Welsch et al., 2009; Belov and van Kuppeveld, 2012;
Romero-Brey et al., 2012; Cortese et al., 2017).
According to our single effect models, ISGs inhibiting RNA
translation initiation and/or promoting the cytoplasmic RNA
degradation led to best fits of the experimental data. However,
this model resulted in a 98,600% increase in the degradation rate
constant with µ̂RV = 987 h
−1, corresponding to an unrealistic
RNA half-life of t1/2 ≈ 2 sec. A model including only IFN
dependent inhibition of the reinfection of naïve cells (promoting
an antiviral state in susceptible cells) was not able to reproduce
the experimental data.
A combination of mechanisms based on model selection
criteria described above resulted in a model including ISG effects
on (1) translation initiation, (2) cytosolic RNA degradation,
and (3) new infection of naïve cells. In this model, DV RNA
degradation was increased by 59%, resulting in a degradation rate
and half-life of µ̂RV = 4.4 h
−1 and t1/2 = 9 min, respectively.
Concerning the reinfection of naïve cells, we observed an
inhibition of about 2%, which was rather negligible. Since cells
were infected with a high MOI in our experiments, i.e., virtually
every cell is infected, viral spread and infection of naïve cells play
only a minor role in our experimental data.
While DV is subject to ISG effects, it has also developed
several strategies to evade the antiviral HIR by antagonizing
and inhibiting the induction of the HIR and the antiviral state
induced by it. Several DV NS proteins have been described
as highly potent inhibitors of IFN signaling and production.
For example, DV NS4B protein has been shown to inhibit
STAT1 phosphorylation (Munoz-Jordan et al., 2003), while the
DV NS5 protein is well-known to degrade STAT2 and thus
result in an inhibition of type I IFN signaling (Ashour et al.,
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FIGURE 7 | Global Sensitivity analysis performed for the DV replication model coupled to the HIR model for polyprotein (A,B), (+)RNA (C,D), and extracellular virus
(E,F), as well as for two different time points: 4 hpi (A,C,E) and 72 hpi (B,D,F). The red line is a negative control used for the sensitivity analysis that is not part of the
model indicating that sensitivities below the red line are negligible. Significant differences to the negative control have been calculated by performing a t-test (p-values:
*** ≤ 0.001, ** ≤ 0.01, * ≤ 0.05).
2009). According to our model simulations, during the course
of infection, DV inhibits both phases of the HIR, the RLR-
mediated induction of IFN by ∼94%, as well as IFN signaling
through the JAK/STAT signaling pathway by ∼ 89%. However,
in our model sensitivity analysis at 72 hpi, we found that
inhibition of the JAK/STAT signaling pathway may be the more
important viral defense mechanism: Increasing the efficiency
of the JAK/STAT pathway activation in a sensitivity analysis
did not lead to viral eradication, but still resulted in ongoing
viral replication with a constant viral RNA concentration of
73%, indicating that DV efficiently counteracts activation of
this pathway. In fact, DV’s ability to efficiently counteract the
JAK/STAT pathway has been confirmed experimentally (Muñoz-
Jordán and Fredericksen, 2010). In contrast, we found that
increasing the efficiency of DV recognition by the RIG-I pathway
led to viral replication at a significantly lower level of only 11%
remaining DVRNA. DV’s ability to target the JAK/STAT pathway
and thus prevent the establishing of an antiviral cellular state
mediated by IFN therefore is an efficient and important viral
survival mechanism.
Comparison to HCV
DV and HCV are both (+)RNA viruses of the family Flaviviridae
and share key features in their lifecycles, but there are striking
differences in their clinical manifestation. While a primary
dengue infection is acute and occasionally associated with
severe complications (DHF, DSS) but does not lead to chronic
infection, the rather asymptomatic acute hepatitis C infection
may develop into lifelong chronic hepatitis Cwith life threatening
secondarymanifestations, such as liver cirrhosis or hepatocellular
carcinoma without successful treatment.
Comparing the dynamics of our DV model with our previous
HCV model (Binder et al., 2013), we observed that the overall
dynamics of luciferase and total (+)RNA in DV is comparable
with the HCV dynamics with a highly dynamic initial phase
that results in steady states for all the measured species. Most
estimated model parameters involved in DV replication showed
higher rate constants in DV compared to HCV (Table 2).
Considering that DV is causing an acute infection, the faster DV
replication seems reasonable, while HCV that may develop into
chronicity is in comparison rather slow in its lifecycle.
Hypothetical Drug Therapy Against DENV
The recent Zika outbreak in Brazil showed the potential health
risks of (re-)emerging viruses. Therefore, a comprehensive
understanding of the virus-host interaction is necessary in order
to suggest antiviral treatment strategies. According to our global
sensitivity analysis and simulated antiviral interventions, the
most effective drug targets in the DV lifecycle are processes
associated with viral entry, translation, and DV RNA synthesis.
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FIGURE 8 | Antiviral intervention study with a drug administration at three different time points (0, 24, and 72 hpi) in (A) A549 and (B) Huh7 cells. The fold change of
infectious virus (ψ) with and without drug administration for the core processes in the DV lifecycle (Equations 29 and 30). A fold change of 1 means no difference
between the model with and without drug administration, while a fold change of 0 shows viral eradication to a successful drug treatment.
TABLE 2 | Comparison of DV and HCV model parameters.
Description Parameter DV HCV
Translation initiation complex formation k1 1,000 ml molecules
−1 h−1 1 molecules−1 h−1 *
RC formation kPin 0.012 ml
2 molecules−2 h−1 9.04e-6 molecules−2 h−1 *
RNA export kPout 1,000 h
−1 0.307 h−1 *
Further replication within RC k3 510 ml molecules
−1 h−1 10−4molecules−1 h−1 *
Replication intermediate complex formation k5 1,000 ml molecules
−1 h−1 10 molecules−1 h−1 *
Initial host factor concentration involved in RC formation HFRC 1 to 4.5 molecules ml
−1 4 to 48 molecules *
Initial ribosome concentration Ribo 2.8 molecules ml−1 628 molecules *
Viral RNA degradation rate µRV 2.8 h
−1 0.363 h−1
Viral protein degradation rate µP 0.001 to 0.0025 h
−1 0.06 h−1
*Parameter values for HCV have been taken from Binder et al. (2013).
However, a drug administration earlier than 24 hpi is highly
unrealistic, since dengue symptoms usually start 4 to 7 days
following a mosquito bite and last for 3 to 10 days (CDC,
2014). However, targeting viral entry is suggested to prevent
viral spread. Later in infection, processes associated with DV
RNA synthesis and virus assembly and release still represented
the most promising drug targets. The antiviral effect on post-
translational and early RNA synthesis proposed by our antiviral
drug intervention study might be achievable by drugs like
Bromocriptine, which has shown antiviral effects against all DV-
Serotypes (Kato et al., 2016). In combination with inhibitors
of the DV RNA-dependent RNA polymerase, effective antiviral
treatment strategies may be possible. Since all processes in the
DV lifecycle depend on host factors, a future antiviral therapy
may focus on host factor-targeting with the development of
pan-serotype or even pan-viral antiviral drugs. As an example,
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the global sensitivity analysis of our model showed a high
impact of the host factors involved in RC formation on
DV RNA and assembly/release. To this end, the inclusion of
further host factors in viral replication models might be an
important challenge for future, in-silico based design of anti-DV
treatment strategies.
Limitations and Outlook
In the current study, we developed the first detailedmathematical
model of the intracellular DV lifecycle, coupling viral entry,
protein translation, RNA replication and assembly and release
with a model of the host cell immune response to infection.
It has been shown in literature that stochastic effects play
an important role in the activation of the IIR and individual
cells in a population respond differently (Rand et al., 2012).
Schmid et al. (2015) have shown that on a single cell level the
IFN response to DV is stochastic and leaky with a fraction
of remaining unprotected cells, in which DV replication is
ongoing, emphasizing the complex nature of the IIR and virus-
host interactions (Schmid et al., 2015). However, we here
studied intracellular processes following DV infection in a single,
“average” cell, and thus we do not take into account inter-
cell differences. Since cells were infected with a high MOI,
where virtually every cell is infected, viral spread is negligible
and therefore, the impact of IFN released from infected cells
to render non-infected, IFN-exposed cells non-permissive to
DV infection is not relevant in our experimental data. We
furthermore neglected cell proliferation in our model, which
would require a multi-scale model combining effects at the cell
population scale with a detailed intracellular model. Overall, we
model an average response of an infected cell in order to study the
DV lifecycle in absence and presence of the HIR, identifying HIR
modes of action and sensitive processes, which might represent
suitable targets for antiviral treatment.
In order to keep the HIR sub-model tractable, we simplified
the activation of the HIR and took only key players of the HIR
into account. Here, we model the recognition of dsRNA that is
present in the cytoplasm, assuming that the replication vesicles
represent a protective environment in which no RNA recognition
occurs. We thus assume that DV replication intermediates
are subject of detection, either when leaked into the cytosol
through the replication vesicle pore or by replication vesicle
decay. However, other cytosolic DV RNA species might be
recognized as well, such as highly structured RNA regions in the
single-stranded genome.
Furthermore, following the HIR activation, we subsume the
different ISG proteins by a single species. This is a simplification
that we make to keep the model simple. It is known that different
ISGs are active at different time points (Metz et al., 2012), even
after uniform IFN treatment (Schmid et al., 2015), hence, we here
model an “average” effect. However, with our coupled model,
we set the basis to study the DV-host interaction. Modeling the
IIR in detail, possibly even coupling it to the adaptive immune
response is needed in order to better understand and prevent
severe dengue complications and to evaluate treatment strategies
that suppress high-level viremia.
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